Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab

Abstract Survival beyond 2 years is rare in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with chemotherapy alone. We describe a patient with ES-SCLC who was treated with carboplatin, etoposide and the programmed death-ligand 1 inhibitor atezolizumab in the IMpower133 study...

Full description

Bibliographic Details
Main Authors: Reyes Bernabé, Stephen V. Liu, Amparo Sánchez-Gastaldo, Miriam Alonso García
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-01-01
Series:Oncology and Therapy
Subjects:
Atezolizumab
Carboplatin
Etoposide
Long-term survival
Small-cell lung cancer
Online Access:https://doi.org/10.1007/s40487-023-00257-0

Internet

https://doi.org/10.1007/s40487-023-00257-0

Similar Items